Clinical decision-making insights for haem/oncs
Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.
These can often cause a lack of confidence in physicians when they are making treatment choices due to the vast number of options available and the very real struggle they face to keep on top of information about them.
With exclusive surveys of the continuing medical education (CME) needs of haematologists/oncologists (haem/oncs), this webinar will look at where physicians are going for their learning needs and what effect the COVID-19 pandemic continues to have.
As part of this, the panel will examine the different needs of community-based physicians treating multiple tumour types, those from academic institutions and experts who deal with specific tumour types.
The Behavioural insights into haem/onc clinical decision-making webinar*, in association with Medscape, took place on Thursday 3rd September from 13:00-14:00 (BST)/14:00-15:00 (CEST).
Our expert panel discussed:
- Why CME is key for community-based haem/oncs
- Clinical challenges among practicing haem/oncs
- The positive impact of CME on healthcare outcomes
- How just-in-time CME can be used to meet physicians’ needs
View the webinar* on demand by clicking on the link in the window above or by clicking here.
Katie Lucero, Director of Outcomes and Insights, Medscape Education
Katie Lucero, PhD, is director of outcomes and insights at Medscape Education Global. She has nearly 20 years of experience in research and evaluation in developmental psychology, public health, health outcomes, and education (K-12 and CME). At Medscape, Dr Lucero oversees and leads strategy in all endeavours where data is used to tell a story. Prior to that, she was director of research and evaluation for McREL International where she was responsible for designing, pursuing, and managing education evaluation and research studies, including government projects. Finally, she directed numerous quality improvement and health outcomes studies during her tenure at a contract research organisation and evaluated public health programmes at the Centers for Disease Control and Prevention (CDC) in the US.
Victoria Harvey-Jones, Associate Director, Clinical Strategy, Medscape Oncology Global
Victoria Harvey-Jones, PhD is an associate director of clinical strategy at Medscape Oncology Global. She has a strong academic background with a first-class degree in Medical Sciences and a PhD in oncology. She also has 3 years’ postdoctoral experience, including time spent at the University of Oxford and the MD Anderson Cancer Centre in Houston, Texas. Dr Harvey-Jones has spent the last 10 years in the medical education and communications industry. She previously helped found touchIME, the Independent Medical Education division at Touch Medical Media, where she was the head of medical and editorial. She joined Medscape Oncology Global as a clinical strategist earlier this year and is passionate about developing impactful educational programmes that support healthcare professionals improve the lives of their patients.
Professor Mohamad Mohty, Head of the Hematology and Cellular Therapy Department, Saint-Antoine Hospital
Mohamad Mohty is full professor of haematology and head of the haematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Haematology Department, Imperial College, Hammersmith Hospital, London, UK. Professor Mohty’s is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.
Moderated by Paul Tunnah, CEO, pharmaphorum
Paul Tunnah is CEO and founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally-recognised news, information and insight portal pharmaphorum.com, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.
* When you click to register for this webinar you will be taken to a website run by BrightTalk who host the webinar and gather your registration data.
This data may then be passed to pharmaphorum media limited, and in turn passed to the company(ies) we are partnering with to bring you the webinar. This data may be used by us and them for occasional marketing purposes. It will not be shared with any further third parties.
By clicking to register for this webinar you give consent for any data you provide to be used in this way.
If at any point you no longer wish to be contacted based on the information you provide during the registration for this webinar, please send an email to firstname.lastname@example.org requesting that your information is deleted in accordance with the General Data Protection Regulation.